The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC).
 
Melanie Mayer
No Relationships to Disclose
 
Nicholas Seewald
Research Funding - Merck
Travel, Accommodations, Expenses - Northwestern Mutual
 
Ernesto Perez
No Relationships to Disclose
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Chethan Ramamurthy
Employment - Merck
Stock and Other Ownership Interests - Merck
Honoraria - Gilead Sciences
Consulting or Advisory Role - Exelixis; SeaGen
Research Funding - Dispersol (Inst); Gilead Sciences (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); SeaGen (Inst)
 
Aram Babcock
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Haojie Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ronac Mamtani
Honoraria - Flatiron Health
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Genentech/Roche; Merck; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Merck
Expert Testimony - King and Spalding LLP; McBrayer Firm